PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors

PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors

Abstract Background The clinical benefit of immunotherapeutic approaches against cancer has been well established although complete responses are only observed in a minority of patients. Combination immunotherapy offers an attractive avenue to develop more effective cancer therapies by improving the...

Full description

Bibliographic Details
Main Authors: Guillaume Beyrend, Esmé van der Gracht, Ayse Yilmaz, Suzanne van Duikeren, Marcel Camps, Thomas Höllt, Anna Vilanova, Vincent van Unen, Frits Koning, Noel F. C. C. de Miranda, Ramon Arens, Ferry Ossendorp
Format: Article
Language:English
Published: BMJ Publishing Group 2019-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Mass cytometry
Combinatorial immunotherapy
T cells
Online Access:http://link.springer.com/article/10.1186/s40425-019-0700-3

Similar Items

Similar Items